4 results
Not approvedWill not start
To determine the prevalence and severity of ASA-related allergic reaction in SM patients.
Approved WMOCompleted
Primary: To evaluate the efficacy of tisagenlecleucel therapy as measured by overall response rate by investigator assessment.Secondary: Duration of response, event free survival, relapse free survival, overall survival, safety, kinetics,…
Approved WMOPending
To determine the prevalence and severity of aspirin-related allergic reactions in SM patients.
Approved WMORecruiting
To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease progression / stable disease at or after the week 12 assessment; or death at any time.